Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 6
Submit an article Journal homepage
717
Views
51
CrossRef citations to date
0
Altmetric
Theme: Parkinson's Disease - Review

Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

Glenda Halliday Neuroscience Research Australia and the University of New South Wales, Barker Street, Randwick 2031, Sydney, NSW, Australia; Neuroscience Research Australia and the University of New South Wales, Barker Street, Randwick 2031, Sydney, NSW, Australia. [email protected]
,
Heather McCann Neuroscience Research Australia, Barker Street, Randwick 2031, Sydney, NSW, Australia; Neuroscience Research Australia, Barker Street, Randwick 2031, Sydney, NSW, Australia
&
Claire Shepherd Neuroscience Research Australia and the University of New South Wales, Barker Street, Randwick 2031, Sydney, NSW, Australia; Neuroscience Research Australia and the University of New South Wales, Barker Street, Randwick 2031, Sydney, NSW, Australia
Pages 673-686 | Published online: 09 Jan 2014

Citations (51)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Thomas Müller. (2021) View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?. Biologics: Targets and Therapy 15, pages 307-316.
Read now
Kurt A Jellinger. (2014) The pathomechanisms underlying Parkinson's disease. Expert Review of Neurotherapeutics 14:2, pages 199-215.
Read now

Articles from other publishers (49)

Edison K. Miyawaki, Shamik Bhattacharyya & Matthew Torre. (2023) Revisiting a Telencephalic Extent of the Ascending Reticular Activating System. Cellular and Molecular Neurobiology 43:6, pages 2591-2602.
Crossref
Lars Tönges, Carsten Buhmann, Stephan Klebe, Jochen Klucken, Eun Hae Kwon, Thomas Müller, David J. Pedrosa, Nils Schröter, Peter Riederer & Paul Lingor. (2022) Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. Journal of Neural Transmission 129:9, pages 1201-1217.
Crossref
Stéphane Prange, Hélène Klinger, Chloé Laurencin, Teodor Danaila & Stéphane Thobois. (2022) Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs & Aging 39:6, pages 417-439.
Crossref
Mengting Luan, Jianing Jin, Ying Wang, Xiaoyuan Li & Anmu Xie. (2022) Association of PGLYRP2 gene polymorphism and sporadic Parkinson's disease in northern Chinese Han population. Neuroscience Letters 775, pages 136547.
Crossref
Javier Blesa, Guglielmo Foffani, Benjamin Dehay, Erwan Bezard & Jose A. Obeso. (2021) Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. Nature Reviews Neuroscience 23:2, pages 115-128.
Crossref
Miriam Vignando, Dominic ffytche, Simon J. G. Lewis, Phil Hyu Lee, Seok Jong Chung, Rimona S. Weil, Michele T. Hu, Clare E. Mackay, Ludovica Griffanti, Delphine Pins, Kathy Dujardin, Renaud Jardri, John-Paul Taylor, Michael Firbank, Grainne McAlonan, Henry K. F. Mak, Shu Leong Ho & Mitul A. Mehta. (2022) Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations. Nature Communications 13:1.
Crossref
Angeliki Spathopoulou, Frank Edenhofer & Lisa Fellner. (2022) Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models. Frontiers in Neurology 12.
Crossref
Michael Beekes. (2021) The Neural Gut–Brain Axis of Pathological Protein Aggregation in Parkinson’s Disease and Its Counterpart in Peroral Prion Infections. Viruses 13:7, pages 1394.
Crossref
Thomas Müller, Bernhard Klaus Mueller & Peter Riederer. (2021) Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 10:4, pages 873.
Crossref
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders 121 163.e16 .
Alice PowellCatriona IrelandSimon J.G. Lewis. (2020) Visual Hallucinations and the Role of Medications in Parkinson’s Disease: Triggers, Pathophysiology, and Management. The Journal of Neuropsychiatry and Clinical Neurosciences 32:4, pages 334-343.
Crossref
Antonio Heras-Garvin & Nadia Stefanova. (2020) From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein. Frontiers in Synaptic Neuroscience 12.
Crossref
Pilar Rivero-Ríos, María Romo-Lozano, Rachel Fasiczka, Yahaira Naaldijk & Sabine Hilfiker. (2020) LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis. Frontiers in Neuroscience 14.
Crossref
Kelly Del Tredici & Heiko Braak. (2020) To stage, or not to stage. Current Opinion in Neurobiology 61, pages 10-22.
Crossref
Hans J. ten DonkelaarHans J. ten Donkelaar, Bart van de Warrenburg, Michèl Willemsen, Benno Küsters, Yoshio Hashizume & Akira Hori. 2020. Clinical Neuroanatomy. Clinical Neuroanatomy 591 667 .
Kurt A. Jellinger. (2019) Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders. Journal of Neural Transmission 126:8, pages 933-995.
Crossref
Chuanxi Tang, Wei Wang, Mingyu Shi, Na Zhang, Xiaoyu Zhou, Xue Li, Chengcheng Ma, Gang Chen, Jie Xiang & Dianshuai Gao. (2019) Meta-Analysis of the Effects of the Catechol-O-Methyltransferase Val158/108Met Polymorphism on Parkinson’s Disease Susceptibility and Cognitive Dysfunction. Frontiers in Genetics 10.
Crossref
Giuseppe Frazzitta, Davide Ferrazzoli, Annarita Folini, Grazia Palamara & Roberto Maestri. (2019) Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors. Frontiers in Neurology 10.
Crossref
Stéphane Prange, Teodor DanailaChloé LaurencinCatherine CaireElise MetereauHélène MerleEmmanuel BroussolleDelphine Maucort-BoulchStéphane Thobois. (2019) Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 92:2.
Crossref
Marco Sancandi, Emma Victoria Schul, Georgia Economides, Andrew Constanti & Audrey Mercer. (2018) Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease. Frontiers in Cellular Neuroscience 12.
Crossref
Kurt A. Jellinger & Amos D. Korczyn. (2018) Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?. BMC Medicine 16:1.
Crossref
Andrew C. Peterson & Chiang-shan R. Li. (2018) Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies. Frontiers in Aging Neuroscience 10.
Crossref
Paola Imbriani, Tommaso Schirinzi, Maria Meringolo, Nicola B. Mercuri & Antonio Pisani. (2018) Centrality of Early Synaptopathy in Parkinson’s Disease. Frontiers in Neurology 9.
Crossref
Stanley Fahn. (2018) The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism & Related Disorders 46, pages S1-S5.
Crossref
D. James Surmeier, Glenda M. Halliday & Tanya Simuni. (2017) Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Experimental Neurology 298, pages 202-209.
Crossref
D. James Surmeier, José A. Obeso & Glenda M. Halliday. (2017) Parkinson's Disease Is Not Simply a Prion Disorder. The Journal of Neuroscience 37:41, pages 9799-9807.
Crossref
J.A. Obeso, M. Stamelou, C.G. Goetz, W. Poewe, A.E. Lang, D. Weintraub, D. Burn, G.M. Halliday, E. Bezard, S. Przedborski, S. Lehericy, D.J. Brooks, J.C. Rothwell, M. Hallett, M.R. DeLong, C. Marras, C.M. Tanner, G.W. Ross, J.W. Langston, C. Klein, V. Bonifati, J. Jankovic, A.M. Lozano, G. Deuschl, H. Bergman, E. Tolosa, M. Rodriguez-Violante, S. Fahn, R.B. Postuma, D. Berg, K. Marek, D.G. Standaert, D.J. Surmeier, C.W. Olanow, J.H. Kordower, P. Calabresi, A.H.V. Schapira & A.J. Stoessl. (2017) Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders 32:9, pages 1264-1310.
Crossref
Lisa Klingelhoefer & H. Reichmann. (2017) Parkinson’s disease as a multisystem disorder. Journal of Neural Transmission 124:6, pages 709-713.
Crossref
Heiko Braak & Kelly Del Tredici. (2017) Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff. Journal of Parkinson's Disease 7:s1, pages S71-S85.
Crossref
D. James Surmeier, José A. Obeso & Glenda M. Halliday. (2017) Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience 18:2, pages 101-113.
Crossref
Lisa Klingelhoefer & Heinz Reichmann. 2017. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders 787 809 .
Kurt A. Jellinger. 2017. Movement Disorders Curricula. Movement Disorders Curricula 43 48 .
Heiko Braak & Kelly Del Tredici. (2016) Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. Cold Spring Harbor Perspectives in Biology 8:11, pages a023630.
Crossref
Morten Gersel Stokholm, Erik Hvid Danielsen, Stephen Jacques Hamilton-Dutoit & Per Borghammer. (2016) Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Annals of Neurology 79:6, pages 940-949.
Crossref
N. L. Rey, S. George & P. Brundin. (2016) Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein. Neuropathology and Applied Neurobiology 42:1, pages 51-76.
Crossref
K. Del Tredici & H. Braak. (2016) Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology . Neuropathology and Applied Neurobiology 42:1, pages 33-50.
Crossref
Heather McCann, Heidi Cartwright & Glenda M. Halliday. (2016) Neuropathology of α-synuclein propagation and braak hypothesis. Movement Disorders 31:2, pages 152-160.
Crossref
James Surmeier, Enrico Zampese, Daniel Galtieri & Paul T. Schumacker. 2016. Mitochondrial Dysfunction in Neurodegenerative Disorders. Mitochondrial Dysfunction in Neurodegenerative Disorders 141 173 .
Lisa Klingelhoefer & Heinz Reichmann. (2015) Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nature Reviews Neurology 11:11, pages 625-636.
Crossref
Ariadna Recasens & Benjamin Dehay. (2014) Alpha-synuclein spreading in Parkinson’s disease. Frontiers in Neuroanatomy 8.
Crossref
David A. Ziegler, Paymon Ashourian, Julien S. Wonderlick, Alison K. Sarokhan, Drazen Prelec, Clemens R. Scherzer & Suzanne Corkin. (2014) Motor impulsivity in Parkinson disease: Associations with COMT and DRD2 polymorphisms. Scandinavian Journal of Psychology 55:3, pages 278-286.
Crossref
K.A. Jellinger. 2014. Pathobiology of Human Disease. Pathobiology of Human Disease 2021 2035 .
Kurt A. Jellinger. 2014. Inflammation in Parkinson's Disease. Inflammation in Parkinson's Disease 25 74 .
Susanne A. Schneider & Jose A. Obeso. 2015. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease 205 220 .
Kurt A. Jellinger. 2013. Emerging Drugs and Targets for Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease 175 216 .
Søren Bang Nielsen, Francesca Macchi, Samuele Raccosta, Annette Eva Langkilde, Lise Giehm, Anders Kyrsting, Anna Sigrid Pii Svane, Mauro Manno, Gunna Christiansen, Niels Christian Nielsen, Lene Oddershede, Bente Vestergaard & Daniel Erik Otzen. (2013) Wildtype and A30P Mutant Alpha-Synuclein Form Different Fibril Structures. PLoS ONE 8:7, pages e67713.
Crossref
Bradley F Boeve. (2013) Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. The Lancet Neurology 12:5, pages 469-482.
Crossref
Michel Goedert, Maria Grazia Spillantini, Kelly Del Tredici & Heiko Braak. (2012) 100 years of Lewy pathology. Nature Reviews Neurology 9:1, pages 13-24.
Crossref
Patrik Brundin & Jeffrey H. Kordower. 2012. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I 221 241 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.